vs
豪洛捷（HOLX）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是豪洛捷的1.4倍（$1.5B vs $1.0B），豪洛捷净利率更高（17.1% vs -3.1%，领先20.2%），豪洛捷同比增速更快（2.5% vs -11.9%），豪洛捷自由现金流更多（$215.2M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
HOLX vs RXO — 直观对比
营收规模更大
RXO
是对方的1.4倍
$1.0B
营收增速更快
HOLX
高出14.4%
-11.9%
净利率更高
HOLX
高出20.2%
-3.1%
自由现金流更多
HOLX
多$224.2M
$-9.0M
两年增速更快
RXO
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.5B |
| 净利润 | $179.1M | $-46.0M |
| 毛利率 | 56.0% | — |
| 营业利润率 | 22.6% | -2.9% |
| 净利率 | 17.1% | -3.1% |
| 营收同比 | 2.5% | -11.9% |
| 净利润同比 | -10.9% | -84.0% |
| 每股收益（稀释后） | $0.79 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRXO
| Q4 25 | $1.0B | $1.5B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $988.0M | $1.0B | ||
| Q2 24 | $1.0B | $930.0M | ||
| Q1 24 | $1.0B | $913.0M |
净利润HOLXRXO
| Q4 25 | $179.1M | $-46.0M | ||
| Q3 25 | $187.2M | $-14.0M | ||
| Q2 25 | $194.9M | $-9.0M | ||
| Q1 25 | $-17.4M | $-31.0M | ||
| Q4 24 | $201.0M | $-25.0M | ||
| Q3 24 | $178.6M | $-243.0M | ||
| Q2 24 | $194.5M | $-7.0M | ||
| Q1 24 | $169.9M | $-15.0M |
毛利率HOLXRXO
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
营业利润率HOLXRXO
| Q4 25 | 22.6% | -2.9% | ||
| Q3 25 | 22.6% | -0.5% | ||
| Q2 25 | 24.9% | — | ||
| Q1 25 | -0.7% | -2.1% | ||
| Q4 24 | 22.5% | -1.4% | ||
| Q3 24 | 23.3% | -1.9% | ||
| Q2 24 | 24.1% | — | ||
| Q1 24 | 20.7% | -1.3% |
净利率HOLXRXO
| Q4 25 | 17.1% | -3.1% | ||
| Q3 25 | 17.8% | -1.0% | ||
| Q2 25 | 19.0% | -0.6% | ||
| Q1 25 | -1.7% | -2.2% | ||
| Q4 24 | 19.7% | -1.5% | ||
| Q3 24 | 18.1% | -23.4% | ||
| Q2 24 | 19.2% | -0.8% | ||
| Q1 24 | 16.7% | -1.6% |
每股收益（稀释后）HOLXRXO
| Q4 25 | $0.79 | $-0.28 | ||
| Q3 25 | $0.84 | $-0.08 | ||
| Q2 25 | $0.86 | $-0.05 | ||
| Q1 25 | $-0.08 | $-0.18 | ||
| Q4 24 | $0.87 | $-0.17 | ||
| Q3 24 | $0.75 | $-1.81 | ||
| Q2 24 | $0.82 | $-0.06 | ||
| Q1 24 | $0.72 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $17.0M |
| 总债务越低越好 | $2.5B | $387.0M |
| 股东权益账面价值 | $5.2B | $1.5B |
| 总资产 | $9.2B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资HOLXRXO
| Q4 25 | $2.4B | $17.0M | ||
| Q3 25 | $2.2B | $25.0M | ||
| Q2 25 | $1.9B | $18.0M | ||
| Q1 25 | $1.6B | $16.0M | ||
| Q4 24 | $2.0B | $35.0M | ||
| Q3 24 | $2.3B | $55.0M | ||
| Q2 24 | $2.4B | $7.0M | ||
| Q1 24 | $2.2B | $7.0M |
总债务HOLXRXO
| Q4 25 | $2.5B | $387.0M | ||
| Q3 25 | $2.5B | $387.0M | ||
| Q2 25 | $2.5B | $387.0M | ||
| Q1 25 | $2.5B | $387.0M | ||
| Q4 24 | $2.5B | $351.0M | ||
| Q3 24 | $2.5B | $352.0M | ||
| Q2 24 | $2.5B | $370.0M | ||
| Q1 24 | $2.6B | $351.0M |
股东权益HOLXRXO
| Q4 25 | $5.2B | $1.5B | ||
| Q3 25 | $5.0B | $1.6B | ||
| Q2 25 | $4.8B | $1.6B | ||
| Q1 25 | $4.6B | $1.6B | ||
| Q4 24 | $4.8B | $1.6B | ||
| Q3 24 | $5.1B | $1.7B | ||
| Q2 24 | $5.0B | $579.0M | ||
| Q1 24 | $4.8B | $582.0M |
总资产HOLXRXO
| Q4 25 | $9.2B | $3.3B | ||
| Q3 25 | $9.0B | $3.2B | ||
| Q2 25 | $8.8B | $3.2B | ||
| Q1 25 | $8.5B | $3.3B | ||
| Q4 24 | $8.7B | $3.4B | ||
| Q3 24 | $9.2B | $3.4B | ||
| Q2 24 | $8.9B | $1.8B | ||
| Q1 24 | $8.7B | $1.8B |
负债/权益比HOLXRXO
| Q4 25 | 0.48× | 0.25× | ||
| Q3 25 | 0.50× | 0.24× | ||
| Q2 25 | 0.52× | 0.24× | ||
| Q1 25 | 0.55× | 0.24× | ||
| Q4 24 | 0.53× | 0.22× | ||
| Q3 24 | 0.49× | 0.21× | ||
| Q2 24 | 0.51× | 0.64× | ||
| Q1 24 | 0.53× | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $-9.0M |
| 自由现金流率自由现金流/营收 | 20.5% | -0.6% |
| 资本支出强度资本支出/营收 | 1.4% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $-8.0M |
8季度趋势，按日历期对齐
经营现金流HOLXRXO
| Q4 25 | $229.9M | $7.0M | ||
| Q3 25 | $355.1M | $23.0M | ||
| Q2 25 | $343.3M | $23.0M | ||
| Q1 25 | $169.4M | $-2.0M | ||
| Q4 24 | $189.3M | $-7.0M | ||
| Q3 24 | $367.0M | $-7.0M | ||
| Q2 24 | $405.8M | $-5.0M | ||
| Q1 24 | $292.4M | $7.0M |
自由现金流HOLXRXO
| Q4 25 | $215.2M | $-9.0M | ||
| Q3 25 | $341.4M | $9.0M | ||
| Q2 25 | $330.5M | $9.0M | ||
| Q1 25 | $153.9M | $-17.0M | ||
| Q4 24 | $172.5M | $-19.0M | ||
| Q3 24 | $350.6M | $-18.0M | ||
| Q2 24 | $385.3M | $-16.0M | ||
| Q1 24 | $279.6M | $-4.0M |
自由现金流率HOLXRXO
| Q4 25 | 20.5% | -0.6% | ||
| Q3 25 | 32.5% | 0.6% | ||
| Q2 25 | 32.3% | 0.6% | ||
| Q1 25 | 15.3% | -1.2% | ||
| Q4 24 | 16.9% | -1.1% | ||
| Q3 24 | 35.5% | -1.7% | ||
| Q2 24 | 38.1% | -1.7% | ||
| Q1 24 | 27.5% | -0.4% |
资本支出强度HOLXRXO
| Q4 25 | 1.4% | 1.1% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 1.3% | 1.0% | ||
| Q1 25 | 1.5% | 1.0% | ||
| Q4 24 | 1.6% | 0.7% | ||
| Q3 24 | 1.7% | 1.1% | ||
| Q2 24 | 2.0% | 1.2% | ||
| Q1 24 | 1.3% | 1.2% |
现金转化率HOLXRXO
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
